PepGen (PEPG) Expected to Announce Quarterly Earnings on Thursday

PepGen (NASDAQ:PEPG) is expected to be announcing its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.71) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, November 13, 2025 at 7:00 AM ET.

PepGen (NASDAQ:PEPG) last announced its earnings results on Thursday, August 7th. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.15. On average, analysts expect PepGen to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

PepGen Price Performance

PEPG opened at $4.53 on Wednesday. The business has a 50 day simple moving average of $3.46 and a 200-day simple moving average of $2.11. The stock has a market capitalization of $148.58 million, a P/E ratio of -1.53 and a beta of 1.95. PepGen has a 12 month low of $0.88 and a 12 month high of $7.50.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Wedbush raised their price target on PepGen from $7.00 to $9.00 and gave the company an “outperform” rating in a report on Thursday, September 25th. HC Wainwright raised their price target on PepGen from $12.00 to $18.00 and gave the company a “buy” rating in a report on Monday, October 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of PepGen in a report on Wednesday, October 8th. Stifel Nicolaus raised their price target on PepGen from $9.00 to $12.00 and gave the company a “buy” rating in a report on Thursday, September 25th. Finally, Guggenheim reissued a “buy” rating and issued a $6.00 price target on shares of PepGen in a report on Wednesday, September 24th. Four equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $9.60.

Insider Transactions at PepGen

In other news, major shareholder Science Enterprises Plc Oxford acquired 200,000 shares of PepGen stock in a transaction that occurred on Tuesday, September 30th. The stock was purchased at an average cost of $3.20 per share, with a total value of $640,000.00. Following the completion of the acquisition, the insider owned 4,955,388 shares in the company, valued at $15,857,241.60. This trade represents a 4.21% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 4.60% of the company’s stock.

Hedge Funds Weigh In On PepGen

Hedge funds and other institutional investors have recently bought and sold shares of the company. Woodline Partners LP acquired a new position in PepGen during the first quarter worth $1,097,000. AQR Capital Management LLC purchased a new position in PepGen during the first quarter worth $122,000. Bridgeway Capital Management LLC increased its position in PepGen by 61.5% during the second quarter. Bridgeway Capital Management LLC now owns 91,923 shares of the company’s stock worth $102,000 after buying an additional 35,000 shares in the last quarter. Qube Research & Technologies Ltd purchased a new position in PepGen during the second quarter worth $81,000. Finally, Marshall Wace LLP purchased a new position in PepGen during the second quarter worth $44,000. 58.01% of the stock is owned by institutional investors and hedge funds.

About PepGen

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.